Connect with us
  • Elysium


Daily News Update: Tuesday, 25 June



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

First UK trial of Deep Brain Stimulation for children with epilepsy begins

A study of a rechargeable device which is mounted onto the skull and attached to electrodes deep in the brain to reduce seizure activity has begun. This is the first UK clinical trial measuring this type of treatment for children with epilepsy. The CADET pilot (Children’s Adaptive Deep brain stimulation for Epilepsy Trial) will now recruit three additional patients with Lennox-Gastaut syndrome, which is funded by the Royal Academy of Engineering, before 22 patients take part in the full trial, which is being funded by GOSH Charity and LifeArc. The study is sponsored by UCL.

Study examines acceptability of teleneurology across neurological conditions

One of the first studies to examine patient acceptability of teleneurology – using telecommunications to improve the delivery of neurological care – and determine factors influencing acceptability across neurological conditions, has found teleneurology was highly acceptable across the full range of patients with different neurological diagnoses. The study, funded by the U.S. Department of Veterans Affairs, also determined that the more medical complexity — having additional diseases — was associated with increased patient satisfaction with teleneurology.

Standardised protocols help hospitals treat strokes faster

New West Virginia University research has illustrated that American Heart Association and American Stroke Association guidelines are effective at speeding up hospitals’ response times for stroke treatment and can be mastered even by members of “ad hoc” medical teams that assemble rapidly on the fly.

Company and financial neuro-rehab news

iRegene Receives IND approval for Parkinson’s Disease clinical trial

The U.S. Food and Drug Administration (FDA) has approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson’s Disease. This makes NouvNeu001 the world’s first chemically induced allogeneic cell therapy product to enter clinical stages for Parkinson’s disease in the US. Previously, the “Combined Phase I/II Clinical Study” of NouvNeu001 had already received approval from China NMPA in August 2023 and demonstrated positive safety and efficacy data in its Phase I trials. On June 20, 2024, iRegene further announced IND approval of NouvNeu001 by the U.S. FDA for the treatment of mid-to-late stage of Parkinson’s disease.

FINTEPLA results examining impact in managing Generalised Tonic-Clonic Seizures

UCB has announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA (fenfluramine) in reducing the frequency of generalised tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) among patients with developmental and epileptic encephalopathies (DEEs). This analysis highlighted a significant reduction in both GTCS and TCS across various DEEs adding to the already established data from the FINTEPLA clinical trial programme.

Neurotechnology news

Advanced neurotechnology in stroke rehabilitation

Frontiers in Neurology has published a new editorial. The Research Topic collection comprised four articles, including two original studies and two review studies. The discussed research delved into the underlying recovery mechanisms after stroke and clinical applications in facilitating motor recovery.